Opening book details…
Can I read Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma on EtoBox?
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma by Adrien Daniel; David Ghez; Camille Ravaiau; Doriane Cavalieri; Olivier Tournilhac; Charles Herbaux; Mélanie Roriz; Mathieu Wemeau; Stéphanie Guillet; Jean Baptiste Bossard; Demarquette Hélène; Eleonore Kaphan; Regny Caroline; Lachenal Florence; Adeline Pierache; Marc Michel; Bertrand Godeau; Louis Terriou is a Medicine article available to read on EtoBox.
What is Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma about?
## Abstract ## Background Autoimmune conditions in B‐cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B‐cell indolent lymphoma treatment. We evaluated the use of ibrutinib in previously treated hematologic immune manifestations associated with B‐cell lymphomas. ## Results We conducted a retrospective multicentric observational study. Patients presenting with active, relapsed/refractory B‐cell lymphoma associated hematological immune manifestation (autoimmune cytopenia, acquired immune‐mediated bleeding disorders) were included. Twenty‐five patients were identified. Median age at ibrutinib introduction was 69 years (range 44–84) and median number of previous treatment lines before ibrutinib was 2 (1–7). Twenty‐two patients (88%) were on concomitant stable treatment at inclusion. Within a median exposure of 8 months (2–35), overall response rate to ibrutinib on immune manifestations was 76% (95% CI, 54.9–90.6); complete response rate 44%. Fourteen patients (63%) were able to be weaned from concomitant treatments. Fourteen patients (56%) presented t
Who reads Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Adrien Daniel; David Ghez; Camille Ravaiau; Doriane Cavalieri; Olivier Tournilhac; Charles Herbaux; Mélanie Roriz; Mathieu Wemeau; Stéphanie Guillet; Jean Baptiste Bossard; Demarquette Hélène; Eleonore Kaphan; Regny Caroline; Lachenal Florence; Adeline Pierache; Marc Michel; Bertrand Godeau; Louis Terriou
- Publisher
- Wiley
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)